History of KRAS-targeting in clinical trials

Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, outlines the impact of the KRAS mutation in the treatment of patients with lung cancer, giving an overview of its history. Dr Lindsay discussess the use of farnesyltransferase inhibitors, MEK inhibitors and synthetic lethality for KRAS-mutant lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.